Long-Term Outcomes of Induction Therapies with Alemtuzumab, Basiliximab or Methylprednisolone in Kidney Transplant Patients with Delayed Graft Function | Zendy

AI Assistant Blog Pricing

Long-Term Outcomes of Induction Therapies with Alemtuzumab, Basiliximab or Methylprednisolone in Kidney Transplant Patients with Delayed Graft Function

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.